Marc N. Casper Affirms Thermo Fisher’s Team-Driven Execution as 2025 Revenue Climbs to $44.6B

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year...

January 30, 2026 | Friday | Company results
Samsung Bioepis Releases First Quarter 2026 U.S. Biosimilar Market Report

Samsung Bioepis Co., Ltd. released its First Quarter 2026 Biosimilar Market Report, marking the twelfth edition of the Quarterly Biosimilar Market Report...

January 26, 2026 | Monday | Company results
Alnylam CEO Yvonne Greenstreet Outlines Five-Year Strategy as Company Reports Strong 2025 Growth and 2026 Outlook

− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues o...

January 13, 2026 | Tuesday | Company results
Early Prescriber Confidence Is Clear,” Says LENZ Therapeutics CEO Eef Schimmelpennink as VIZZ Launch Exceeds Expectations

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-...

January 09, 2026 | Friday | Company results
Ironwood CEO Tom McCourt Outlines Strong 2026 Outlook, Forecasting Up to $1.175B in LINZESS U.S. Net Sales and Adjusted EBITDA Above $300M

- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater...

January 05, 2026 | Monday | Company results
Repare Therapeutics Enters Definitive Agreement to Be Acquired by Xeno Therapeutics

Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...

November 17, 2025 | Monday | News
Merck CEO Belén Garijo Confirms Confident Momentum Across Healthcare And Life Science

  Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...

November 14, 2025 | Friday | Company results
Rapid Micro Biosystems CEO Robert Spignesi Highlights Strong Q3 Execution and Record Consumable Revenue

Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recu...

November 10, 2025 | Monday | Company results
Marc N. Casper Highlights Thermo Fisher’s 10% Adjusted EPS Growth and Strategic AI Collaboration with OpenAI in Strong Q3 2025 Results

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 27, ...

October 23, 2025 | Thursday | Company results
Pierre Boulud Credits GO∙28 Plan as bioMérieux Delivers Strong Profitability in H1 2025

  Pierre Boulud, Chief Executive Officer of bioMérieux, set the tone for the company’s first-half 2025 performance: “With a stron...

September 16, 2025 | Tuesday | Company results
Thierry Bernard Leads QIAGEN to Strong Q2 2025 Results with $534 Million in Sales and Upgraded Outlook

Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above out...

August 06, 2025 | Wednesday | Company results
New CEO Dr Michael Grosse Charts Confident Course for Sartorius, Backed by Pharma-Focused Expansion

Group sales revenue up 6.1 percent in the first six months As expected, continued positive trend in recurring business with consumables Bioproce...

July 22, 2025 | Tuesday | Company results
Merck CEO Belén Garijo Steers Strong Q1 as Process Solutions Powers Growth and Strategic Vision

Net sales increased organically by 2.5% to € 5.3 billion EBITDA pre up organically by 5.8% to € 1.5 billion All three b...

May 15, 2025 | Thursday | Company results
Illumina Posts $1.04B in Q1 2025 Revenue as CEO Jacob Thaysen Cautions on Weaker Full-Year Outlook Amid Tariff Pressures and China Headwinds

Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...

May 09, 2025 | Friday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close